

Atypical Pathogens and Challenges in Community-Acquired Pneumonia

KRISTOPHER P. THIBODEAU, LCDR, MC, USN, and ANTHONY J. VIERA, LCDR, MC, USNR
Naval Hospital Jacksonville, Jacksonville, Florida

Atypical organisms such as *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, and *Legionella pneumophila* are implicated in up to 40 percent of cases of community-acquired pneumonia. Antibiotic treatment is empiric and includes coverage for both typical and atypical organisms. Doxycycline, a fluoroquinolone with enhanced activity against *Streptococcus pneumoniae*, or a macrolide is appropriate for outpatient treatment of immunocompetent adult patients. Hospitalized adults should be treated with cefotaxime or ceftriaxone plus a macrolide, or with a fluoroquinolone alone. The same agents can be used in adult patients in intensive care units, although fluoroquinolone monotherapy is not recommended; ampicillin-sulbactam or piperacillin-tazobactam can be used instead of cefotaxime or ceftriaxone. Outpatient treatment of children two months to five years of age consists of high-dose amoxicillin given for seven to 10 days. A single dose of ceftriaxone can be used in infants when the first dose of antibiotic is likely to be delayed or not absorbed. Older children can be treated with a macrolide. Hospitalized children should be treated with a macrolide plus a beta-lactam inhibitor. In a bioterrorist attack, pulmonary illness may result from the organisms that cause anthrax, plague, or tularemia. Sudden acute respiratory syndrome begins with a flu-like illness, followed two to seven days later by cough, dyspnea and, in some instances, acute respiratory distress. (Am Fam Physician 2004;69:1699-706. Copyright© 2004 American Academy of Family Physicians)

Members of various family practice departments develop articles for "Practical Therapeutics." This article is one in a series coordinated by the Department of Family Medicine at Naval Hospital Jacksonville, Jacksonville, Fla. Guest editor of the series is Anthony J. Viera, LCDR, MC, USNR.

Community-acquired pneumonia (CAP) affects approximately 4.5 million adults in the United States annually.¹ About one third of these adults require hospitalization.¹ The mortality rate among hospitalized patients with CAP varies each year and can reach 35 percent.² While *Streptococcus pneumoniae* causes up to 70 percent of CAP cases, atypical pathogens are responsible for 30 to 40 percent of cases³ and may be copathogens in other cases. Even with a knowledge of some of the common characteristics of infections with atypical organisms (Table 1),⁴ determining the specific pathogen on the basis of clinical, radiologic, and laboratory findings is difficult and usually done retrospectively, if at all.

Atypical Pathogens

MYCOPLASMA PNEUMONIAE

Mycoplasma pneumoniae causes a wide range of respiratory infections, including pneumonia, tracheobronchitis, and upper respiratory tract infection. Only 3 to 10 percent of persons infected with *M. pneumoniae* develop

pneumonia.⁵ Because *M. pneumoniae* infection becomes more common with increasing age, it is particularly important to consider this agent in elderly patients.⁶

M. pneumoniae infection occurs throughout the year but can cause periodic outbreaks within small communities. Transmission is by person-to-person contact, and infection spreads slowly, most often within closed populations (e.g., households, schools, businesses).

M. pneumoniae is the pathogen most often associated with atypical pneumonia. Onset is insidious, over several days to a week. Constitutional symptoms, which usually are present, include headache exacerbated by a cough, malaise, myalgias, and sore throat. The cough is usually dry, paroxysmal, and worse at night.

The clinical course of pneumonia caused by *M. pneumoniae* is usually mild and self-limited. The mortality rate is approximately 1.4 percent.² However, pulmonary complications can be significant and include effusion, empyema, pneumothorax, and respiratory distress syndrome.

TABLE 1

Diagnostic Features Suggestive of Community-Acquired Pneumonia Caused by Atypical Pathogens

Diagnostic feature	Mycoplasma pneumoniae	Chlamydia pneumoniae pneumonia	Legionella species pneumonia
History			
Abdominal pain	-	-	+
Confusion	+/-	-	+
Diarrhea	+/-	-	+
Ear pain	+/-	-	-
Headache (mild)	+	-	-
Myalgias	+	+/-	+
Pleuritic pain	+/-	-	+
Sore throat	+	+	-
Physical signs			
Cardiac involvement	+/-	-	-
Lobar consolidation	+/-	-	+/-
Hemoptysis	-	-	+
Pharyngitis (nonexudative)	+	+	-
Rash	+/-	-	-
Raynaud's phenomenon	+/-	-	-
Chest radiograph	Patchy infiltrate	Funnel-shaped or circumscribed infiltrate	Patchy consolidation
Laboratory test results			
Cold agglutinins	+	-	-
Hyponatremia	-	-	+
Leukocytosis	+/-	-	+
Microscopic hematuria	-	-	+
Transaminase elevation	-	-	+

- = rarely; +/- = occasionally; + = often.

Adapted with permission from Cotton EM, Strampfer MJ, Cunha BA. Legionella and mycoplasma pneumonia—a community hospital experience with atypical pneumonias. Clin Chest Med 1987;8:441-53.

M. pneumoniae infection may be associated with several extrapulmonary manifestations. Skin manifestations include erythema multiforme, erythema nodosum, maculopapular and vesicular eruptions, and urticaria. Neurologic derangements include aseptic meningitis, cerebral ataxia, encephalitis, Guillain-Barré syndrome, and transverse myelitis. The production of cold agglutinins can result in hemolytic anemia, especially when *M. pneumoniae* titers are high. Finally, complications such as myocarditis, pancreatitis, pericarditis, and polyarthritis can occur.

CHLAMYDIA PNEUMONIAE

Chlamydia pneumoniae is an obligate intracellular organism capable of persistent latent infection. Humans are the only known reservoir. Transmission results from contact with respiratory secretions, with an incubation period of several weeks.

By the age of 20 years, one half of persons in the United States have detectable levels of antibody to *C. pneumoniae*.⁷ The antibody is present in 75 percent of elderly persons.⁷ *C. pneumoniae* infection is more likely to occur in older patients with comorbid diseases than in those who are otherwise healthy.⁸

Patients with *C. pneumoniae* infection often present with sore throat, headache, and a cough that can persist for months if treatment is not initiated early.⁹ Sputum is usually scant or nonexistent, and a low-grade fever is usually present. Chest radiographs tend to show less extensive infiltrates than are seen with other causes of pneumonia, although significant infiltrates have been reported.¹⁰

Most cases of *C. pneumoniae* infection are mild, but severe disease can occur, necessitating admission to an intensive care unit. The mortality rate has been estimated to be 9 percent, and death usually is associated with secondary infection and underlying comorbid disease.²

LEGIONELLA PNEUMOPHILA

Like *C. pneumoniae*, Legionella species are intracellular organisms. *Legionella pneumophila* is the most pathogenic species, and several serotypes have been identified. Serotype 1 has been associated with most reported human cases of pneumonia caused by *L. pneumophila*.¹¹

Infection occurs from exposure to legionellae organisms in the environment. Person-to-person spread has not been reported. Legionellae are found most commonly in freshwater and man-made water systems. The pathogens also can be found in moist soil, especially near streams and ponds. Man-made systems for heating and cooling water can be prime environments for the proliferation of legionellae, because of conditions such as temperatures between 32°C (89.6°F) and 45°C (113°F), stagnation of water, and the presence of scale sediment and amoebas.¹² Condensers, cooling towers, respiratory therapy equipment, showers, water faucets, and whirlpools have been associated with outbreaks of legionellosis.¹³

Risk factors for the development of legionellosis include

TABLE 2

Empiric Antibiotic Regimens for Community-Acquired Pneumonia*

Outpatient treatment

Doxycycline (Vibramycin)

or

Fluoroquinolone (gatifloxacin [Tequin], levofloxacin [Levaquin], moxifloxacin [Avelox]) with enhanced activity against *Streptococcus pneumoniae*

or

Macrolide (azithromycin [Zithromax], clarithromycin [Biaxin], erythromycin)

Inpatient treatment

Patient not in intensive care unit

Extended-spectrum cephalosporin (cefotaxime [Claforan], ceftriaxone [Rocephin]) plus a macrolide

or

Fluoroquinolone alone

Patient in intensive care unit

Cefotaxime or ceftriaxone plus a macrolide

or

Cefotaxime or ceftriaxone plus a fluoroquinolone

or

Beta-lactam (ampicillin-sulbactam [Unasyn], piperacillin-tazobactam [Zosyn]) plus a macrolide

or

Beta-lactam plus a fluoroquinolone

Other circumstances

Structural lung disease: antipseudomonal agent (piperacillin [Pipracil], piperacillin-tazobactam, a carbapenem, or cefepime [Maxipime]) plus a fluoroquinolone (including high-dose ciprofloxacin [Cipro])

Beta-lactam allergy: fluoroquinolone with or without clindamycin (Cleocin)

Aspiration pneumonia: fluoroquinolone with or without clindamycin, metronidazole (Flagyl), or a beta-lactam

*—*Penicillin-resistant S. pneumoniae may be resistant to macrolides and doxycycline. Pneumonia thought to be secondary to S. pneumoniae should be treated until the patient is afebrile for 72 hours. Pneumonia thought to be caused by atypical pathogens (i.e., Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella species) should be treated for at least two weeks. Pathogens with necrotizing potential (e.g., Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella species, anaerobes) also should be treated for at least two weeks.*

Adapted with permission from Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. *Clin Infect Dis* 2000;31:372.

overnight stays outside the home, recent home plumbing work, renal or liver failure, diabetes, malignancy, and other conditions that compromise the immune system.¹⁴

Legionnaires' disease may present with a wide spectrum of symptoms ranging from mild cough and low-grade fever to high fever, altered mental status, and respiratory failure.¹⁵ Nonspecific symptoms may occur early in the

disease and include headache, muscle aches, anorexia, and malaise.¹⁵ Diarrhea and other gastrointestinal symptoms are present in 20 to 40 percent of cases.¹⁵ Leukocytosis is a common laboratory finding, and the sputum Gram stain often shows an abundance of inflammatory cells without a predominance of organisms.¹¹

Among cases of CAP with atypical causes, legionnaires' disease has the most severe clinical course, and illness can become progressively more severe if the infection is not treated appropriately and early. Although extrapulmonary manifestations are rare, legionellosis has been implicated in cases of myocarditis, pericarditis, and prosthetic valve endocarditis, as well as glomerulonephritis, pancreatitis, and peritonitis.¹⁵ When CAP is caused by *Legionella* species, the mortality rate is 14 percent.²

Therapy

Therapy for pneumonia is empiric because specific pathogens usually are not identified at the time treatment is initiated. Several classes of antibiotics are effective against atypical pathogens. However, because *C. pneumoniae* and *Legionella* species are intracellular organisms and *M. pneumoniae* lacks a cell wall, beta-lactams are not effective.


Erythromycin and, in some cases, tetracycline have been traditional choices for the treatment of pneumonia caused by atypical pathogens. There are few (if any) clinical trials demonstrating the efficacy of erythromycin for *Legionella* infection. However, erythromycin and tetracycline are effective against *M. pneumoniae* and have been shown to reduce symptom duration in *C. pneumoniae* infection.^{5,8}

Newer macrolides such as azithromycin (Zithromax) and clarithromycin (Biaxin) have good activity against *M. pneumoniae*, *C. pneumoniae*, and *Legionella* species, and generally are better tolerated than erythromycin.¹⁶⁻²⁰ Doxycycline (Vibramycin) also is effective,²¹ typically is associated with fewer gastrointestinal side effects, and is a less expensive alternative.

Fluoroquinolones have demonstrated excellent activity against *M. pneumoniae*, *C. pneumoniae*, and *Legionella* species. In addition, fluoroquinolones have the advantage of once-daily dosing and excellent bioavailability, whether they are given intravenously or orally.²²⁻²⁵

The Infectious Diseases Society of America (IDSA)²⁶ has published a comprehensive, evidence-based guideline to the management of CAP in adults who are immunocompetent. Empiric treatment recommendations are based on whether

Determining Mortality Risk for Community-Acquired Pneumonia



STEP 3. Determine the risk class.

Risk class and associated mortality rate			
Points	Class	Mortality rate (%)	Recommended site of care
No predictors in step 1	I	0.1	Outpatient
<70	II	0.6	Outpatient
71 to 90	III	0.9	Outpatient or inpatient
91 to 130	IV	9.3	Inpatient
>130	V	21.0	Inpatient

FIGURE 1. Prediction rule for community-acquired pneumonia.

Information from Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. *N Engl J Med* 1997;336:246-8.

patients are treated as outpatients or inpatients (Table 2).²⁶ The decision to hospitalize can be guided by the mortality prediction rule shown in Figure 1.²⁷

Blood cultures do not have to be performed before outpatient therapy is started. However, the IDSA²⁶ recommends performing blood cultures in hospitalized patients, if possible before antibiotics are administered. Sputum Gram stain and culture also are recommended in these patients. Antibiotic therapy should be initiated within four hours of hospitalization.²⁸

Treatment Challenges

FAILURE OF OUTPATIENT MANAGEMENT

Patients treated with antibiotics may fail outpatient management for a number of reasons, such as antibiotic resistance, poor compliance with or intolerance of oral antibiotics, obstructing lesions (e.g., foreign body, cancer), empyema, and incorrect diagnosis.²⁶ Table 3^{26,29} lists alternate diagnoses that may mimic CAP.

PARAPNEUMONIC EFFUSION AND EMPYEMA

Up to 57 percent of patients with CAP have pleural effusions on chest radiographs.³⁰ Empyema, defined as pus in the pleural space, should be drained by chest tube, image-guided catheter, thoracoscopy, or thoracotomy.²⁶ Even if the pleural fluid does not contain free-flowing frank pus, it should be drained when the pH level is less than 7.2 or the Gram stain is positive.²⁶ Some experts recommend drainage for any parapneumonic effusion that measures more than 10 mm on a lateral decubitus radiograph.³⁰

CHILDREN

An evidence-based guideline on the management of CAP in children, developed by a children's hospital, is available online.³¹ Pneumonia should be suspected in a child who presents with fever and tachypnea. Because infection with an atypical pathogen is unlikely in children two months to five years of age, the recommended treatment in these patients is high-dose amoxicillin (80 to 90 mg per kg daily) for seven to 10 days. A cephalosporin or macrolide is recommended in those who are allergic to penicillin. Macrolides are recommended for the treatment of CAP in children older than five years, because of the increased likelihood of infection with *M. pneumoniae* or *C. pneumoniae* in older children. Macrolides also provide coverage for *S. pneumoniae*.

Hospitalization should be considered for any child with

Antibiotic therapy should be initiated within four hours of hospitalization for community-acquired pneumonia.

TABLE 3

Conditions that May Mimic Community-Acquired Pneumonia

Acute respiratory distress syndrome	Interstitial pneumonitis
Atelectasis	Malignant pleural effusion
Bronchiolitis obliterans with organizing pneumonia	Neoplasm
Churg-Strauss syndrome	Occupational lung disease
Collagen vascular disease	Pulmonary embolus
Congestive heart failure	Pulmonary hemorrhage or infarction
Drug-induced lung disease	Radiation pneumonitis
Idiopathic pulmonary fibrosis	Sarcoidosis
Inflammatory lung disease	Wegener's granulomatosis

Information from references 26 and 29.

CAP and is necessary if a child requires oxygen or intravenous therapy, or if treatment compliance or follow-up may be an issue. Treatment with a macrolide plus a beta-lactam (high-dose amoxicillin or parenteral ceftriaxone [Rocephin]) should be considered in children with more severe pneumonia. Children treated as outpatients should have a follow-up examination within 24 to 72 hours.³¹

ELDERLY PATIENTS

Elderly patients with CAP may present with few respiratory signs or symptoms of pneumonia. Instead, they may have altered mental status or a history of falls.³² Elderly patients also are more likely to have significant comorbid conditions, such as chronic obstructive pulmonary disease, congestive heart failure, or renal disease, and are particularly susceptible to silent aspiration.^{32,33}

Aspiration pneumonia should be suspected in patients with a condition that compromises consciousness or swallowing, especially when the chest radiograph shows infiltrates in dependent segments of the lung. Antibiotics effective against anaerobic organisms from the mouth

Long-term oral hygiene and appropriate pneumococcal and influenza vaccinations can reduce rates of community-acquired pneumonia in immunocompetent persons.

TABLE 4
Criteria for Hospitalization of Nursing Home Patients with Pneumonia

Hospitalize the patient if two or more of the following are present:

- Respiratory rate >30 breaths per minute or 10 breaths above baseline
- Oxygen saturation <90 percent on room air
- Systolic blood pressure <90 mm Hg or 20 mm Hg less than baseline
- Oxygen requirement of 3 L per minute more than baseline
- Uncontrolled chronic obstructive pulmonary disease, congestive heart failure, or diabetes
- If previously conscious, cannot be awakened
- New or increased agitation

With the presence of any one of the above, hospitalization also is indicated if proper physical and human resources are not available (e.g., nursing staff, physician, oxygen, suction equipment, laboratory access, intravenous fluids).

Information from Hutt E, Kramer A. Evidence-based guidelines for management of nursing home-acquired pneumonia. *J Fam Pract* 2002; 51:713.

The Authors

KRISTOPHER P. THIBODEAU, LCDR, MC, USN, is staff family physician at Naval Hospital Sigonella, Italy. He received his medical degree from the Uniformed Services University of the Health Sciences F. Edward Hébert School of Medicine, Bethesda, Md., and completed a residency in family medicine at Naval Hospital Jacksonville, Jacksonville, Fla.

ANTHONY J. VIERA, LCDR, MC, USNR, is a staff family physician at Naval Hospital Jacksonville and assistant professor of family medicine at the Uniformed Services University of the Health Sciences F. Edward Hébert School of Medicine. He received his medical degree from the Medical University of South Carolina College of Medicine, Charleston, and completed a residency in family medicine at Naval Hospital Jacksonville.

Address correspondence to LCDR Kristopher P. Thibodeau, MC, USN, Naval Hospital Sigonella, PSC 836, Box 0036, FPO AE 09636-0036 (e-mail: kthibodeau@sig.med.navy.mil). Reprints are not available from the authors.

TABLE 5

Treatment Recommendations for Nursing Home Residents with Community-Acquired Pneumonia

- Amoxicillin-clavulanate potassium (Augmentin), 500 mg orally every eight hours
- Fluoroquinolone with enhanced activity against *Streptococcus pneumoniae* (e.g., levofloxacin [Levaquin], 500 mg orally once daily)
- Ceftriaxone (Rocephin), 500 to 1000 mg intramuscularly once daily, or cefotaxime (Claforan), 500 mg intramuscularly every 12 hours

Adapted with permission from Marrie TJ. Community-acquired pneumonia in the elderly. *Clin Infect Dis* 2000;31:1072.

should be given (Table 2).²⁶

Pneumonia acquired in a nursing home has a high rate of morbidity and mortality (up to 44 percent).³⁴ It is the leading infectious illness requiring transfer from a nursing home to a hospital.³² Guidelines on when to hospitalize are provided in Table 4.³⁴ Recommended treatment regimens for patients in nursing homes are summarized in Table 5.³²

IMMUNOCOMPROMISED PATIENTS

The guidelines and recommendations given throughout this article are intended for immunocompetent patients. Immunocompromised patients may develop pneumonia from organisms such as *Pneumocystis carinii*, *Candida* species, and *Aspergillus* species, as well as other opportunistic organisms not reviewed in this article.

Prevention Strategies

Despite evidence showing that pneumococcal vaccine significantly reduces the occurrence of pneumococcal pneumonia in persons who are immunocompetent, immunization rates are modest at best.³⁵ Vaccination is more likely when it is recommended by a patient's physician or by someone in the physician's office.³⁵ Although influenza is not reviewed in this article, it is an important contributor to CAP; therefore, patients at risk for CAP should be given annual influenza vaccination.²⁶ In addition, long-term oral hygiene appears to reduce the incidence of pneumonia among elderly persons living in nursing homes.³⁶

BIOTERRORISM AGENTS THAT MAY CAUSE PNEUMONIA

Several organisms that can be used in biological weapons may cause illness that presents as CAP (Table 6).^{26,37} It is important for physicians to be aware of potential bioterrorist tactics and risks, and the resulting health care demands. Information on bioterrorism response is available on the American Academy of Family Physicians Web site (<http://www.aafp.org/btresponse.xml>).

SUDDEN ACUTE RESPIRATORY SYNDROME

TABLE 6

Bioterrorism Agents that May Cause Pneumonia-like Illness

Disease	Causative agent	Clinical features	Ancillary findings or diagnostic clue	Diagnosis	Treatment	Duration of treatment	Prophylaxis after exposure
Anthrax	<i>Bacillus anthracis</i>	Fever, malaise, cough, acute respiratory distress syndrome, shock	Widened mediastinum on chest radiograph	Gram stain of unspun peripheral blood, blood culture	Ciprofloxacin (Cipro) or other fluoroquinolone, doxycycline (Vibramycin), or penicillin (if susceptible)	60 days	Ciprofloxacin, amoxicillin, or doxycycline for 60 days
Plague	<i>Yersinia pestis</i>	High fever, malaise, cough, bloody sputum, shock	Blood-tinged sputum within 24 hours of onset	Gram-negative bipolar coccobacillus on Gram stain and culture of blood, sputum, cerebrospinal fluid	Doxycycline or fluoroquinolone	10 days	Doxycycline or fluoroquinolone for 7 days
Tularemia	<i>Francisella tularensis</i>	Fever, prostration, cough	Chest radiograph shows focal infiltrate, hilar adenopathy	Culture of blood, sputum, pharyngeal specimen (high risk to laboratory personnel)	Doxycycline	14 days	Doxycycline or tetracycline for 14 days
Q Fever	<i>Coxiella burnetii</i>	Fever, cough, shortness of breath, weight loss, chest pain	Minimally productive cough, vague substernal chest pain or tightness	Blood culture, PCR, serology	Doxycycline, tetracycline	5 to 7 days	Tetracycline or doxycycline for five days starting on day 8 to 12
Brucellosis	<i>Brucella</i> species	Fever, myalgias, cough	Undulating fever, bone-associated osteoarticular symptoms	Blood culture, marrow culture, immunoassay, PCR (high risk to laboratory personnel)	Doxycycline plus rifampin (Rifadin) or streptomycin	6 weeks	None recommended

PCR = polymerase chain reaction.

Information from references 26 and 37.

Periodically, an epidemiologic investigation prompted by an outbreak of pneumonia leads to the identification of a previously unrecognized organism.²⁶ Sudden acute respiratory syndrome (SARS) is an example. SARS, which is thought to have originated in a Hong Kong apartment building, is caused by a coronavirus (SARS-CoV). During the SARS outbreak of 2002 to 2003, over 8,000 probable cases were reported from 29 different countries. Twenty-nine cases were reported in the United States.³⁸

SARS presents with a prodrome of symptoms of a flu-like illness (fever, chills, myalgias, headache, diarrhea),

followed in two to seven days by cough, dyspnea and, possibly, acute respiratory distress syndrome.^{26,38} The case-fatality rate for SARS is about 9.6 percent.³⁸ No deaths in the United States have been linked to SARS.³⁸ Information about SARS and travel guidelines are available at the Centers for Disease Control and Prevention Web site (<http://www.cdc.gov/ncidod/sars/>).

The authors indicate that they do not have any conflicts of interest. Sources of funding: none reported.

The opinions and assertions contained herein are the private views of

Pneumonia

the authors and are not to be construed as official or as reflecting the views of the U.S. Navy Medical Corps or the U.S. Navy at large.

REFERENCES

1. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. *Clin Ther* 1998;20:820-37.
2. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. *JAMA* 1996; 275:134-41.
3. Green DS, San Pedro GS. Empiric therapy of community-acquired pneumonia. *Semin Respir Infect* 2000;15:227-33.
4. Cotton EM, Strampfer MJ, Cunha BA. Legionella and mycoplasma pneumonia—a community hospital experience with atypical pneumonias. *Clin Chest Med* 1987;8:441-53.
5. Liu C. Mycoplasma pneumonia. In: Hoepflich PD, Jordan MC, Ronald AR, eds. *Infectious diseases: a treatise of infectious processes*. 5th ed. Philadelphia: Lippincott, 1994:411-16.
6. Marston BJ, Plouffe JF, File TM Jr, Hackman BA, Salstrom SJ, Lipman HB, et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance study in Ohio. The Community-Based Pneumonia Incidence Study Group. *Arch Intern Med* 1997;157:1709-18.
7. Kuo CC, Jackson LA, Campbell LA, Grayston JT. *Chlamydia pneumoniae* (TWAR). *Clin Microbiol Rev* 1995;8:451-61.
8. Kauppinen M, Saikku P. Pneumonia due to *Chlamydia pneumoniae*: prevalence, clinical features, diagnosis, and treatment. *Clin Infect Dis* 1995;21(suppl 3):S244-52.
9. Wright SW, Edwards KM, Decker MD, Grayston JT, Wang S. Prevalence of positive serology for acute *Chlamydia pneumoniae* infection in emergency department patients with persistent cough. *Acad Emerg Med* 1997;4:179-83.
10. McConnell CT Jr, Plouffe JF, File TM, Mueller CF, Wong KH, Skelton SK, et al. Radiographic appearance of *Chlamydia pneumoniae* (TWAR strain) respiratory infections. CBPIS Study Group. Community-based Pneumonia Incidence Study. *Radiology* 1994;192:819-24.
11. File TM Jr, Tan JS, Plouffe JF. The role of atypical pathogens: *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, and *Legionella pneumophila* in respiratory infection. *Infect Dis Clin North Am* 1998;12:569-92,vii.
12. Shands KN, Ho JL, Meyer RD, Gorman GW, Edelstein PH, Mallison GF, et al. Potable water as a source of Legionnaires' disease. *JAMA* 1985;253:1412-6.
13. Butler JC, Fields BS, Breiman RF. Prevention and control of Legionellosis. *Infect Dis Clin Pract* 1997;6/7:458-64.
14. Straus WL, Plouffe JF, File TM Jr, Lipman HB, Hackman BH, Salstrom SJ, et al. Risk factors for domestic acquisition of legionnaires disease. Ohio Legionnaires Disease Group. *Arch Intern Med* 1996;156:1685-92.
15. Stout JE, Yu VL. Legionellosis. *N Engl J Med* 1997;337:682-7.
16. Cassell GH, Drnec J, Waites KB, Pate MS, Duffy LB, Watson HL, et al. Efficacy of clarithromycin against *Mycoplasma pneumoniae*. *J Antimicrob Chemother* 1991;27(suppl A):47-59.
17. Fernandes PB, Bailor R, Swanson R, Hanson CW, McDonald E, Ramer N, et al. In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. *Antimicrob Agents Chemother* 1986;30:865-73.
18. Kuo CC, Jackson LA, Lee A, Grayston JT. In vitro activities of azithromycin, clarithromycin, and other antibiotics against *Chlamydia pneumoniae*. *Antimicrob Agents Chemother* 1996;40:2669-70.
19. Retsema J, Girard A, Schelkly W, Manousos M, Anderson M, Bright G, et al. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. *Antimicrob Agents Chemother* 1987;31:1939-47.
20. Vergis EN, Indorf A, File TM Jr, Phillips J, Bates J, Tan J, et al. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial. *Arch Intern Med* 2000;160:1294-300.
21. Gupta SK, Sarosi GA. The role of atypical pathogens in community-acquired pneumonia. *Med Clin North Am* 2001;85:1349-65,vii.
22. File TM Jr, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. *Antimicrob Agents Chemother* 1997;41:1965-72.
23. Hammerschlag MR, Hyman CL, Roblin PM. In vitro activities of five quinolones against *Chlamydia pneumoniae*. *Antimicrob Agents Chemother* 1992;36:682-3.
24. Meyer RD. Role of the quinolones in the treatment of legionellosis. *J Antimicrob Chemother* 1991;28:623-5.
25. File TM Jr. Fluoroquinolones and respiratory tract infections: do they work? *Infect Dis Clin Pract* 1997;6(suppl 2):S59-66.
26. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. *Clin Infect Dis* 2000;31:347-82.
27. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. *N Engl J Med* 1997;336:243-50.
28. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Infectious Diseases Society of America. *Clin Infect Dis* 2003;37:1405-33.
29. Cabrerós LJ, Rajendran R, Drimoussis A, Brandstetter RD. Radiographic mimics of pneumonia. Pulmonary disorders to consider in differential diagnosis. *Postgrad Med* 1996;99:139-42,145-6.
30. Sahn SA. Management of complicated parapneumonic effusions. *Am Rev Respir Dis* 1993;148:813-7.
31. Evidence-based clinical practice guidelines. Community-acquired pneumonia in children 60 days to 17 years of age. Cincinnati, Ohio: Cincinnati Children's Hospital Medical Center, 2002. Accessed March 19, 2004 at: <http://www.cincinnatichildrens.org/svc/dept-div/health-policy/ev-based/pneumonia.htm>.
32. Marrie TJ. Community-acquired pneumonia in the elderly. *Clin Infect Dis* 2000;31:1066-78.
33. Kikuchi R, Watabe N, Konno T, Mishina N, Sekizawa K, Sasaki H. High incidence of silent aspiration in elderly patients with community-acquired pneumonia. *Am J Respir Crit Care Med* 1994; 150:251-3.
34. Hutt E, Kramer A. Evidence-based guidelines for management of nursing home-acquired pneumonia. *J Fam Pract* 2002;51:709-16.
35. Zimmerman RK, Santibanez TA, Fine MJ, Janosky JE, Nowalk MP, Bardella IJ, et al. Barriers and facilitators of pneumococcal vaccination among the elderly. *Vaccine* 2003;21:1510-7.
36. Yoneyama T, Yoshida M, Matsui T, Sasaki H. Oral care and pneumonia. Oral Care Working Group [Letter]. *Lancet* 1999;354:515.
37. Eitzen E. Medical management of biological casualties: handbook.